Tangible Materials. As soon as reasonably possible, but no later than the respective time periods as specified in the Technology Transfer Plan after the Effective Date, Spark shall, at its own cost, transfer to Pfizer the samples of tangible materials relating to or embodying the Spark Technology licensed hereunder that are specified in the Technology Transfer Plan.
Appears in 3 contracts
Sources: License Agreement, License Agreement (Spark Therapeutics, Inc.), License Agreement (Spark Therapeutics, Inc.)